A higher proportion of sleep medicine providers vs. patients reported CPAP over tirzepatide as their preferred treatment option for comorbid obesity and obstructive sleep apnea, according to data ...

KeyBanc Capital Markets maintained its Overweight rating and $274.00 price target on ResMed (NYSE: RMD) stock following industry observations. The target aligns with broader analyst expectations, with ...

According to InvestingPro data, ResMed currently trades near its 52-week high of $263.05, having delivered a 20.72% return over the past year.

ResMed is also doubling its US manufacturing footprint in June 2025. GLP-1 drugs remain a positive for now. ResMed gathered data on 1.4 million sleep apnea patients prescribed a GLP-1 drug. It found ...

Type: Auto | Features: Touchscreen, on/off button, advanced event detection | Weight: Not stated ResMed is one of the best-known CPAP machine brands, so it's no surprise that the AirSense 11 ...

We award ResMed a narrow moat rating based on switching costs and intangible assets, which have helped the company achieve high customer adherence rates and above-average industry growth. In ...

As the chorus trilled in the musical Oklahoma! – the farmer and the cowboy should be friends. In the case of Resmed, the developers of a new class of anti-obesity drugs look like being far more ...

ResMed Inc. (NYSE:RMD) Q2 2025 Earnings Call Transcript January 30, 2025 ResMed Inc. beats earnings expectations. Reported EPS is $2.43, expectations were $2.32. Operator: Welcome to the Q2 Fiscal ...

ResMed reported $1.28 billion in revenue for Q2 2025, a 10% increase year-over-year, aligning closely with analysts' revenue estimate of $1.27 billion. Non-GAAP EPS reached $2.42, surpassing the ...